Spyre Therapeutics, Inc. SYRE Allocation of deferred offering costs against proceeds of issuance of common stock
Allocation of deferred offering costs against proceeds of issuance of common stock at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept syre:DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s allocation of deferred offering costs against proceeds of issuance of common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s allocation of deferred offering costs against proceeds of issuance of common stock?
- Spyre Therapeutics, Inc. (SYRE) reported allocation of deferred offering costs against proceeds of issuance of common stock of $3K in Q1 2026.
- What does allocation of deferred offering costs against proceeds of issuance of common stock mean?
- This metric tracks the portion of costs incurred in connection with equity offerings that are capitalized and subsequently offset against the gross proceeds of the issuance. It reflects the accounting treatment of legal, accounting, and underwriting fees associated with raising capital. By netting these costs against proceeds, the company clarifies the actual net capital raised from shareholders.